DINAH PARUMS

Freelance Medical and Science Writer, Editor, Journalist & Consultant



dvparums@gmail.com

dr-dinah-parums.com

linkedin.com/in/dinahparums

visualcv.com/dinahparums

LINKS TO PUBLICATIONS

Dr Dinah Parums | Publications Website: http://www.dr-dinah-parums.com

GoogleScholar: https://scholar.google.com/citations?user=2BxIcIAAAAAJ&hl=en

ResearchGate: https://www.researchgate.net/profile/Dinah-Parums

Academia.Edu: https://independent.academia.edu/DinahParums

PubFacts: https://www.pubfacts.com/author/Dinah+Parums

PublicationsList: http://publicationslist.org/dinah.parums

Dr Dinah Parums | Patents: http://patents.justia.com/inventor/dinah-parums

Author, Healthcare-Arena: https://healthcare-arena.co.uk/author/dinahparums/

Dr Dinah Parums' **Teaching and Medical Education** publishing experience can be found on: https://www.visualcv.com/dinahparumsteaching

PROFILE

Dr. Dinah Parums works as a home-based, self-employed, freelance medical editor, writer, consultant, and journalist, since becoming physically disabled.

In September 2018, Dinah became Director of DVP Editorial Limited.

Dinah has more than 100 peer-reviewed publications, more than 5,000 citations, an H-index of 32, and a Google Scholar i10-index of 37.

She has more than 20 years of postgraduate medical teaching experience and has supervised five PhD students. Dinah has written and edited a postgraduate medical textbook, Essential Clinical Pathology (Blackwell Science Ltd. Oxford. ISBN 0-632-03088-7). Dinah has worked as a Clinical Editor for the British Medical Journal (BMJ), and is currently a peer reviewer for several biomedical journals.

Dinah has undergraduate medical degrees from the University of Cambridge (B.A., M.A) and clinical medical degrees from Oxford University Medical School (B.M., B.Ch.). Her Ph.D. in experimental pathology is from the University of Cambridge. Dinah was awarded research fellowships from the British Heart Foundation, Wolfson College, Oxford, and Darwin College, Cambridge. She has also held visiting fellowships in the USA at the Massachusetts General Hospital (MGH) and Stanford University Medical School.

Dinah did her postgraduate specialist training in the Nuffield Department of Pathology, John Radcliffe Hospital, Oxford, as Clinical Lecturer and postgraduate Clinical Tutor in Pathology. She was awarded Membership of the Royal College of Pathologists (MRCPath) in 1991 and the Fellowship (FRCPath) in 1999, and was also awarded the Fellowship of the American College of Chest Physicians (FCCP) in 1999. She held senior clinical and academic positions at the University of Cambridge, and the Royal Postgraduate Medical School, Imperial College, University of London.

Between 1994 and 2002, Dinah was an External Examiner for the Royal College of Pathologists (MRCPath) and a member of the US/Canadian Academy of Pathologists (US/CAP).

Dinah has more than 10 years of experience working as a consultant to the pharmaceutical industry and as a Principal Pharmaceutical Physician.

Dinah is a 1441 Foundation Member and Henry VI Circle Legacy Group Member of King's College, Cambridge University.

In support of her current role, Dr Dinah Parums is a member of the *National Union of Journalists* (NUJ), the *American Medical Writers Association* (AMWA), the *European Medical Writers Association* (EMWA) and the *International Society for Medical Publication Professionals* (ISMPP). She is familiar with the current guidelines from the *International Committee of Medical Journal Editors* (ICMJE), the *Committee on Publication Ethics* (COPE), the *AMA Manual of Style* (10th Edition) and the current *Good Publication Practice* (GPP3/4) guidelines.

Dr Parums' **Teaching and Medical Education** publishing experience can be found on: https://www.visualcv.com/dinahparumsteaching

PUBLICATIONS

Publication websites:

ORCID No: 0000-0003-0145-5464

Google Scholar

Academia.Edu

ResearchGate

PubFacts

PublicationsList.

Books:

Parums, D.V. (Editor). **Essential Clinical Pathology**. Blackwell Science Ltd. Oxford. 1996. ISBN 0-632-03088-7.

This 700-page postgraduate teaching book contains 500 full-colour figures. It represents a complete clinical pathology (laboratory medicine) 'core' course textbook for medical students, based on the Editor's teaching experience running the Oxford University Medical School's clinical pathology teaching over three years. One-third of this book is written by the Editor, with contributions in Haematology, Biochemistry, Immunology and Microbiology from 14 other authors.

Peer Reviewed Publications:

1. **Parums DV.** Editorial: Surveillance of Seasonal Respiratory Syncytial Virus (RSV) Infection in Children and Vulnerable Adults Drives Vaccine Development and New Immunization Programs. Med Sci Monit. 2025;31:e949558. doi: 10.12659/MSM.949558. PMID: 40308086. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC12054328/

2. **Parums DV**. A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment Response. Med Sci Monit. 2025;31:e949300. doi: 10.12659/MSM.949300. PMID: 40259565. Available from: https://pmc.ncbi.nlm.nih.gov/articles/pmid/40259565/

3. **Parums DV.** Editorial: Rapid Testing for the Avian Influenza A(H5N1) Virus is Urgently Required as Infections in Poultry and Dairy Cows are on the Rise, and so is Transmission to Humans. Med Sci Monit, 2025;31:e949109. doi: 10.12659/MSM.949109. PMID: 40165538. Available from: https://pmc.ncbi.nlm.nih.gov/articles/pmid/40165538/

4. **Parums DV.** Editorial: The World Health Organization (WHO) Updated List of Emerging and Potentially Pandemic Pathogens Includes Yersinia pestis as Plague Vaccines Await Clinical Trials. Med Sci Monit, 2025; 31: e948672. doi: 10.12659/MSM.948672. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11881517/

5. **Parums DV.** A Review of CAR T Cells and Adoptive T-Cell Therapies in Lymphoid and Solid Organ Malignancies. Med Sci Monit, 2025;31:e948125. doi: 10.12659/MSM.948125. PMID: 39893510. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11800685/

6. **Parums DV**. Editorial: Current Approaches to Screening for Lung Cancer in Smokers and Non-Smokers. Med Sci Monit. 2025;31:e948255. doi: 10.12659/MSM.948255. PMID: 39891449. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11796283/

7. **Parums DV.** Editorial: The Human Cell Atlas. What Is It and Where Could It Take Us? Med Sci Monit. 2025; 30: e947707. doi: 10.12659/MSM.947707. PMID: 39741433. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11702441/

8. **Parums DV.** Editorial: The 2024 Revision of the Declaration of Helsinki and its Continued Role as a Code of Ethics to Guide Medical Research. Med Sci Monit, 2024; 30: e947428. doi: 10.12659/MSM.947428. PMID: 39616449. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11619173/

9. **Parums DV.** A Review of Emerging Viral Pathogens and Current Concerns for Vertical Transmission of Infection. Med Sci Monit, 2024; 30: e947335. doi: 10.12659/MSM.947335. PMID: 39578400. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11600638/

10. **Parums DV**. Editorial: Artificial Intelligence (AI), Digital Image Analysis, and the Future of Cancer Diagnosis and Prognosis. Med Sci Monit. 2024;30:e947038. doi: 10.12659/MSM.947038. PMID: 39482925. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC11536697/

11. **Parums DV**. Editorial: Potentials and Pitfalls in Targeting Glucagon-Like Peptide-1 (GLP-1) in the Management of Increasing Levels of Obesity. Med Sci Monit. 2024;30:e946675. doi: 10.12659/MSM.946675. PMID: 39350608. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11453121/

12. **Parums DV.** Long COVID or Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) and the Urgent Need to Identify Diagnostic Biomarkers and Risk Factors. Med Sci Monit. 2024;30:e946512. doi: 10.12659/MSM.946512. PMID: 39289865. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418572/

13. **Parums DV**. Editorial: Reasons for Increasing Global Concerns for the Spread of Mpox. Med Sci Monit, 2024; 30: e946343. doi: 10.12659/MSM.946343. PMID: 39217431. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376131/

14. **Parums DV.** Editorial: Genome Editing Goes Beyond CRISPR with the Emergence of 'Bridge' RNA Editing. Med Sci Monit. 2024; 30: e945933. doi: 10.12659/MSM.945933. PMID: 39086277. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302237/

15. **Parums DV.** A Review of the Increasing Global Impact of Climate Change on Human Health and Approaches to Medical Preparedness. Med Sci Monit, 2024; 30: e945763. doi: 10.12659/MSM.945763. PMID: 38988000. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302257/

16. **Parums DV**. Editorial: The Global Threats of Increasing Antimicrobial Resistance Require New Approaches to Drug Development, Including Molecular Antimicrobial Adjuvants. Med Sci Monit, 2024; 30: e945583. doi: 10.12659/MSM.945583. PMID: 38967286. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11305064/

17. **Parums DV**. Editorial: Concerns as Highly Pathogenic Avian Influenza (HPAI) Virus of the H5N1 Subtype is Identified in Dairy Cows and Other Mammals. Med Sci Monit. 2024; 30: e945315. doi: 10.12659/MSM.945315. PMID: 38822579. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11155697/

18. **Parums DV**. A Review of the Current Status of Disease-Modifying Therapies and Prevention of Alzheimer's Disease. Med Sci Monit. 2024; 30: e945091. doi: 10.12659/MSM.945091. PMID: 38736218. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11097689/

19. **Parums DV**. Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi). Med Sci Monit. 2024; 30: e944927. doi: 10.12659/MSM.944927. PMID: 38689550. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071689/

20. **Parums DV.** Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection - Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug Resistance. Med Sci Monit. 2024; 30: e944600. doi: 10.12659/MSM.944600. PMID: 38557932. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10996429/

21. **Parums DV.** A Review of the Resurgence of Measles, a Vaccine-Preventable Disease, as Current Concerns Contrast with Past Hopes for Measles Elimination. Med Sci Monit, 2024; 30: e944436. doi: 10.12659/MSM.944436. PMID: 38525549. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10946219/

22. **Parums DV.** Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia. Med Sci Monit, 2024; 30: e944204. doi: 10.12659/MSM.944204. PMID: 38425279. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913280/

23. **Parums DV**. Editorial: Global Health Concerns as Vaccine-Preventable Infections Including SARS-CoV-2 (JN.1), Influenza, Respiratory Syncytial Virus (RSV), and Measles Continue to Rise. Med Sci Monit, 2024; 30: e943911. doi: 10.12659/MSM.943911. PMID: 38298093. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845785/

24. **Parums DV**. A Review of IgA Vasculitis (Henoch-Schönlein Purpura) Past, Present, and Future. Med Sci Monit. 2024; 30: e943912. doi: 10.12659/MSM.943912. PMID: 38281080. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10832303/

25. **Parums DV**. Editorial: Climate Change and the Spread of Vector-Borne Diseases, Including Dengue, Malaria, Lyme Disease, and West Nile Virus Infection. Med Sci Monit. 2024; 29: e943546. doi: 10.12659/MSM.943546. PMID: 38161310. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10768291/

26. **Parums DV**. Editorial: Outbreaks of Post-Pandemic Childhood Pneumonia and the Re-Emergence of Endemic Respiratory Infections. Med Sci Monit. 2023; 29: e943312. doi: 10.12659/MSM.943312. PMID: 38037346. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10702145/

27. **Parums DV**. Editorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared. Med Sci Monit. 2023; 29: e942960. doi: 10.12659/MSM.942960, PMID: 37908161. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626992/

28. **Parums DV**. Editorial: The Increasing Relevance of Case Reports in Medical Education and Clinical Practice – and How to Write Them. Am J Case Rep 2023; 24: e942670. doi:10.12659/AJCR.942670. PMID: 37777861. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10556536/

29. **Parums DV**. Editorial: Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023 Guidelines for COPD, Including COVID-19, Climate Change, and Air Pollution. Med Sci Monit. 2023; 29: e942672. doi:10.12659/MSM.942672. PMID: 37777859. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552569/

30. **Parums DV**. Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2. Med Sci Monit. 2023;29:e942244. doi: 10.12659/MSM.942244. PMID: 37654205. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478578/

31. **Parums DV**. Editorial: First Regulatory Approval for Allogeneic Pancreatic Islet Beta Cell Infusion for Adult Patients with Type 1 Diabetes Mellitus. Med Sci Monit, 2023; 29: e941918. doi: 10.12659/MSM.941918. PMID: 37525584. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403990/

32. **Parums DV**. Editorial: Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). Updated Terminology for the Long-Term Effects of COVID-19. Med Sci Monit. 2023;29:e941595. doi: 10.12659/MSM.941595. PMID: 37392031. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321154/

33. **Parums DV.** Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic Preparedness. Med Sci Monit. 2023;29:e941209. doi: 10.12659/MSM.941209. PMID: 37259578. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240961/

34. **Parums DV**. Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy. Med Sci Monit, 2023;29:e940911 doi: 10.12659/MSM.940911. PMID: 37122279. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161797/

35. **Parums DV**. Editorial: Effective Direct-Acting Antiviral Treatments Support Global and National Programs to Eliminate Hepatitis C. Med Sci Monit. 2023;29:e940519. doi: 10.12659/MSM.940519. PMID: 37002682. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075002/

36. **Parums DV**. Editorial: Global Surveillance of Highly Pathogenic Avian Influenza Viruses in Poultry, Wild Birds, and Mammals to Prevent a Human Influenza Pandemic. Med Sci Monit. 2023;29:e939968. doi: 10.12659/MSM.939968. PMID: 36855861. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9987167/

37. **Parums DV**. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread. Med Sci Monit. 2023;29:e939580. doi: 10.12659/MSM.939580. PMID: 36722047. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901170/

38. **Parums DV**. Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030. Med Sci Monit. 2023;29:e939357. doi: 10.12659/MSM.939357. PMID: 36587274. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814194/

39. **Parums DV**. Editorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic. Med Sci Monit, 2022; 28: e939088. doi: 10.12659/MSM.939088. PMID: 36453055. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724454/

40. **Parums DV**. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Med Sci Monit, 2022; 28: e938746. doi: 10.12659/MSM.938746. PMID: 36317327. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636839/

41. **Parums DV.** Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir. Med Sci Monit 2022; 28:e938532. doi: 10.12659/MSM.938532. PMID: 36181334. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536144/

42. **Parums DV**. Editorial: Current Status of Non-Endemic Global Infections with the Monkeypox Virus. Med Sci Monit. 2022;28:e938203. doi: 10.12659/MSM.938203. PMID: 36047039. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9447348/

43. **Parums DV**. Editorial: Long-Term Effects of Symptomatic and Asymptomatic SARS-CoV-2 Infection in Children and the Changing Pathogenesis of Common Childhood Viruses Driven by the COVID-19 Pandemic. Med Sci Monit. 2022;28:e937927. doi: 10.12659/MSM.937927. PMID: 35909366. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354561/

44. **Parums DV**. Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2. Med Sci Monit. 2022;28:e937676. doi: 10.12659/MSM.937676. PMID: 35775166. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254723/

45. **Parums DV**. Editorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19. Med Sci Monit. 2022;28:e937048. doi: 10.12659/MSM.937048. PMID: 35490309. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069970/

46. **Parums DV**. Editorial: First Approval of the Protein-Based Adjuvanted Nuvaxovid (NVX-CoV2373) Novavax Vaccine for SARS-CoV-2 Could Increase Vaccine Uptake and Provide Immune Protection from Viral Variants. Med Sci Monit. 2022;28:e936523. doi: 10.12659/MSM.936523. PMID: 35228506. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897963/

47. **Parums DV**. Editorial: The 2022 World Health Organization (WHO) Priority Recommendations and Response to the Omicron Variant (B.1.1.529) of SARS-CoV-2. Med Sci Monit 2022; 28:e936199. doi: 10.12659/MSM.936199. PMID: 35102132. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817616/

48. **Parums DV**. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients. Med Sci Monit. 2022;28:e935952. doi: 10.12659/MSM.935952. PMID: 34972812. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8729033/

49. **Parums DV.** Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19. Med Sci Monit. 2021;27:e935624. doi: 10.12659/MSM.935624. PMID: 34848673. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647456/

50. **Parums DV**. Editorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems During the COVID-19 Pandemic? Med Sci Monit. 2021;27:e935299. doi: 10.12659/MSM.935299. PMID: 34719663. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570045/

51. **Parums DV**. Editorial: The 2021 European Society of Cardiology (ESC) Guidelines on the Real-World Prevention of Atherosclerotic Cardiovascular Disease (ASCVD). Med Sci Monit. 2021;27:e935172. doi: 10.12659/MSM.935172. PMID: 34690345. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555443/

52. **Parums DV**. Editorial: Global Initiatives Support the Use and Regulation of Digital Health Technology During the COVID-19 Pandemic. Med Sci Monit. 2021;27:e935123. doi: 10.12659/MSM.935123. PMID: 34657930. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532519/

53. **Parums DV**. Editorial: Multisystem Inflammatory Syndrome in Adults (MIS-A) and the Spectrum of COVID-19. Med Sci Monit. 2021;27:e935005. doi: 10.12659/MSM.935005. PMID: 34629462. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518511/

54. **Parums DV**. Editorial: A Decline in Influenza During the COVID-19 Pandemic and the Emergence of Potential Epidemic and Pandemic Influenza Viruses. Med Sci Monit. 2021;27:e934949. doi: 10.12659/MSM.934949. PMID: 34602605. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499673/

55. **Parums DV**. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC). Med Sci Monit. 2021;27:e934854. doi: 10.12659/MSM.934854. PMID: 34565792. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482802/

56. **Parums DV**. Editorial: Autoantibodies to Components of the Immune System, Including Type 1 Interferons, and the Risk of Severe COVID-19. Med Sci Monit. 2021;27:e934766. doi: 10.12659/MSM.934766. PMID: 34538868. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462125/

57. **Parums DV**. Editorial: The First Monoclonal Antibody Vaccine to Prevent Malaria Heralds a New Era of Malaria Vaccines to the Plasmodium falciparum Circumsporozoite Protein (PfCSP). Med Sci Monit. 2021;27:e934676. doi: 10.12659/MSM.934676. PMID: 34511592. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447852/

58. **Parums DV**. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. Med Sci Monit. 2021;27:e934625. doi: 10.12659/MSM.934625. PMID: 34483336. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8434768/

59. **Parums DV**. Editorial: Reporting Clinical Trials with Important Modifications Due to Extenuating Circumstances, Including the COVID-19 Pandemic: CONSERVE 2021. Med Sci Monit. 2021;27:e934514. doi: 10.12659/MSM.934514. PMID: 34456331. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415037/

60. **Parums DV**. Editorial: Review Articles, Systematic Reviews, Meta-Analysis, and the Updated Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 Guidelines. Med Sci Monit. 2021;27:e934475. doi: 10.12659/MSM.934475. PMID: 34421116. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8394590/

61. **Parums DV**. Editorial: Post-Exposure Prophylactic Neutralizing Monoclonal Antibodies to SARS-CoV-2 for Individuals at High Risk for COVID-19. Med Sci Monit. 2021;27:e934393. doi: 10.12659/MSM.934393. PMID: 34393218. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378223/

62. **Parums DV.** Editorial: Updates from the World Health Organization (WHO) on Global Treatment Recommendations for Drug-Susceptible and Multidrug-Resistant Tuberculosis. Med Sci Monit. 2021;27:e934292. doi: 10.12659/MSM.934292. PMID: 34366429. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8362336/

63. **Parums DV**. Editorial: The National COVID Cohort Collaborative Consortium Combines Population Data with Machine Learning to Evaluate and Predict Risk Factors for the Severity of COVID-19. Med Sci Monit. 2021;27:e934171. doi: 10.12659/MSM.934171. PMID: 34334785. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343537/

64. **Parums DV.** Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein. Med Sci Monit. 2021;27:e934077. doi: 10.12659/MSM.934077. PMID: 34305135. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8323472/

65. **Parums DV**. Editorial: Maternal SARS-CoV-2 Infection and Pregnancy Outcomes from Current Global Study Data. Med Sci Monit. 2021;27:e933831. doi: 10.12659/MSM.933831. PMID: 34219126. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268975/

66. **Parums DV**. Editorial: Artificial Intelligence (AI) in Clinical Medicine and the 2020 CONSORT-AI Study Guidelines. Med Sci Monit. 2021;27:e933675. doi: 10.12659/MSM.933675. PMID: 34176921. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252890/

67. **Parums DV**. Editorial: Revised World Health Organization (WHO) Terminology for Variants of Concern and Variants of Interest of SARS-CoV-2. Med Sci Monit. 2021;27:e933622. doi: 10.12659/MSM.933622. PMID: 34149046. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230247/

68. **Parums DV**. Editorial: Registries and Population Databases in Clinical Research and Practice. Med Sci Monit. 2021;27:e933554. doi: 10.12659/MSM.933554. PMID: 34149048. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212698/

69. **Parums DV**. Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care. Med Sci Monit. 2021;27:e933446. doi: 10.12659/MSM.933446. PMID: 34092779. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194290/

70. **Parums DV**. Editorial: COVID-19 and Multisystem Inflammatory Syndrome in Children (MIS-C). Med Sci Monit. 2021;27:e933369. doi: 10.12659/MSM.933369. PMID: 34075014. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176784/

71. **Parums DV**. Editorial: 2021 European Society for Medical Oncology (ESMO) Recommendations on Laboratory Diagnostics for RET Gene Fusions and Mutations: A New Era in Targeted Therapy for RET-Altered Solid Tumors. Med Sci Monit. 2021;27:e933206. doi: 10.12659/MSM.933206. PMID: 34024902. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162049/

72. **Parums DV**. Editorial: mRNA Vaccines and Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections. Med Sci Monit. 2021;27:e932915. doi: 10.12659/MSM.932915. PMID: 33942804. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106254/

73. **Parums DV**. Editorial: SARS-CoV-2 mRNA Vaccines and the Possible Mechanism of Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). Med Sci Monit. 2021;27:e932899. doi: 10.12659/MSM.932899. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086413/

74. **Parums DV**. Editorial. The Role of the Pathologist in the Era of Personalized Medicine. SM J Clin Pathol. 2016;1(1):1003. Available from: https://www.jsmcentral.org/sm-clinical-pathology/fulltext_smjcp-v1-1003.pdf

75. **Parums DV**. Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc). 2014;50(7):503-25. doi: 10.1358/dot.2014.50.7.2185913. PMID: 25101332. Available from: https://www.academia.edu/10248939/Current_Status_of_Targeted_Therapy_in_Non_Small_Cell_Lung_Cancer_NSCLC_

76. **Parums DV**. Invited Review: Status of Immune Therapy in Non Small-Cell Lung Cancer (NSCLC). Drugs Future 2014;39(7): 469-475. doi: 10.1358/dof.2014.39.7.2185935. Available from: https://www.academia.edu/14478210/Status_of_Immune_Therapy_in_Non_Small_Cell_Lung_Cancer_NSCLC_

77. Donovan MJ, Kotsianti A, Bayer-Zubek V, Verbel D, Teverovskiy M, Cordon-Cardo C, Costa J, Greco FA, Hainsworth JD, **Parums DV**. A systems pathology model for predicting overall survival in patients with refractory, advanced non small-cell lung cancer treated with gefitinib. Eur J Cancer. 2009 May;45(8):1518-26. doi: 10.1016/j.ejca.2009.02.004. Epub 2009 Mar 9. PMID: 19272767. Available from: https://www.ejcancer.com/article/S0959-8049(09)00091-4/fulltext

78. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, **Parums DV**, Speake G, Holloway B, Bunn Jr PA, Franklin WA. Epidermal Growth Factor Immunohistochemistry: Comparison of Antibodies and Cut-off Points to Predict Benefit from Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non-Small Cell Lung Cancer. Cancer. 2008 Mar 1;112(5):1114-21. doi: 10.1002/cncr.23282. PMID: 18219661. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355966/

79. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, **Parums DV**, Botwood, Holloway B. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006 Nov

1;24(31):5034-42. doi: 10.1200/JCO.2006.06.3958. PMID: 17075123. Available from: https://ascopubs.org/doi/pdf/10.1200/JCO.2006.06.3958

80. Torsney E, Charlton R, **Parums DV**, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res. 2002 Sep;51(9):464-70. doi: 10.1007/pl00012413. PMID: 12365720. Available from: https://link.springer.com/article/10.1007/PL00012413

81. Katz SD, **Parums DV**. Sympathetic activation by sildenafil. Circulation. 2001 Nov 27;104(22):E119-20. PMID: 11723034. Available from: https://www.ahajournals.org/doi/epub/10.1161/circ.104.22.e119

82. Ray-Chaudhuri N, Kine DA, Tijani SO, **Parums DV**, Cartlidge N, Strong NP, Dayan MR. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002 May;86(5):530-2. doi: 10.1136/bjo.86.5.530. PMID: 11973248. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1771122/

83. Luckraz H, **Parums DV**, Dunning J. Reverse saphenous interposition vein graft repair of a giant atherosclerotic aneurysm of the left anterior descending coronary artery. J Thorac Cardiovasc Surg. 2002 Apr;123(4):817-20. doi: 10.1067/mtc.2002.121290. PMID: 11986613. Available from: https://www.jtcvs.org/article/S0022-5223(02)80294-X/fulltext

84. De Soyza AG, Dark JH, **Parums DV**, Curtis A, Corris PA. Donor-acquired small cell lung cancer following pulmonary transplantation. Chest. 2001 Sep;120(3):1030-1. doi: 10.1378/chest.120.3.1030. PMID: 11555546. Available from: https://journal.chestnet.org/article/S0012-3692(15)50193-1/fulltext

85. Arthur H, Torsney E, Ure J, Smith A, Wilson D, Charlton RG, **Parums DV**, Jowett T, Burn J, Diamond A. Endoglin, an ancillary TGF Beta Receptor, is Required for Extraembryonic Angiogenesis and Plays a Key Role in Heart Development. Dev Biol. 2000 Jan 1;217(1):42-53. doi: 10.1006/dbio.1999.9534. PMID: 10625534. Available from: https://www.sciencedirect.com/science/article/pii/S0012160699995349

86. Pagano D, Townend JN, **Parums DV**, Bonser RS, Camici PG. Hibernating Myocardium: Morphological Correlates of Inotropic Stimulation and Glucose Uptake. Heart. 2000 Apr;83(4):456-61. doi: 10.1136/heart.83.4.456. PMID: 10722551. Available from: https://heart.bmj.com/content/83/4/456.long

87. Kumar RP, Smith DA, Hilton CJ, **Parums DV**. A Case of Epithelioid Haemangioendothelioma (EHE) of the Lung with Bronchial Brushing Cytology. Cytopathology. 1999 Apr;10(2):132-6. doi: 10.1046/j.1365-2303.1999.00111.x. PMID: 10211620. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1365-2303.1999.00111.x

88. Crilley JG, Owens WA, **Parums DV**. A Dissection with a Difference: An Unusual Case of Ascending Aortic Dissection Secondary to Granulomatous Aortitis. Hosp Med. 1998 Nov;59(11):892-3. PMID: 10197126. https://eurekamag.com/research/045/057/045057665.php

89. **Parums DV.** Invited Commentary: Histiocytosis X. Thorax. 1998 Apr;53(4):322-3. doi: 10.1136/thx.53.4.322. PMID: 9741379. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1745190/

90. Gorog DA, Rakhit R, **Parums DV**, Laffan M, Davies GJ. Raised Factor VIII is Associated with Coronary Thrombotic Events. Heart. 1998 Oct;80(4):415-7. doi: 10.1136/hrt.80.4.415. PMID: 9875127. Available from: https://heart.bmj.com/content/80/4/415.long

91. Marchbank AJ, **Parums DV**, Westaby S. Tricuspid valve repair in a mountaineer. Ann Thorac Surg. 1998 Feb;65(2):537-9. doi: 10.1016/s0003-4975(97)01355-6. PMID: 9485262. Available from: https://www.annalsthoracicsurgery.org/article/S0003-4975(97)01355-6/fulltext

92. Leonard A, Corris P, **Parums, DV.** Amiodarone pulmonary toxicity. BMJ. 1997 Jun 21;314(7097):1831-2. doi: 10.1136/bmj.314.7097.1831b. PMID: 9224103. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2126921/

93. Walton LJ, Powell JT, **Parums DV**. Unrestricted Usage of Immunoglobulin Heavy Chain Genes in B Cells Infiltrating the Wall of Atherosclerotic Abdominal Aortic Aneurysms. Atherosclerosis. 1997 Nov;135(1):65-71. doi: 10.1016/s0021-9150(97)00152-4. PMID: 9395274. Available from: https://www.atherosclerosis-journal.com/article/S0021-9150(97)00152-4/pdf

94. Buttery LDK, Springall DR, Chester AH, Evans TJ, Standfield N, **Parums DV**, Yacoub MH, Polak JM. Inducible Nitric Oxide Synthase is Present within Human Atherosclerotic Lesions and Promotes the Formation and Activity of Peroxynitrite. Lab Invest. 1996 Jul;75(1):77-85. PMID: 8683942. Available from: https://eurekamag.com/research/031/900/031900261.php

95. **Parums DV**, Ashton MD, Mason JC, Haskard DO. Thy-1 expression by new vessels associated with atherosclerosis. J Pathol 1996; 179:A46-A46. ISSN: 0022-3417.

96. Kennedy P, Parry AJ, **Parums DV**, Pillai R. Myxoma of the aortic valve. Ann Thorac Surg. 1995 May;59(5):1221-3. doi: 10.1016/0003-4975(94)00969-e. PMID: 7733728. Available from: https://www.annalsthoracicsurgery.org/article/0003-4975(94)00969-E/pdf

97. Ramshaw AL, Roskell DE, **Parums DV**. Cytokine gene expression in aortic adventitial inflammation associated with advanced atherosclerosis (chronic periaortitis). J Clin Pathol. 1994 Aug;47(8):721-7. doi: 10.1136/jcp.47.8.721. PMID: 7962625. Available from: https://jcp.bmj.com/content/jclinpath/47/8/721.full.pdf

98. **Parums DV**. Invited review: The Arteritides. Histopathology. 1994 Jul;25(1):1-20. doi: 10.1111/j.1365-2559.1994.tb00593.x. PMID: 7959641. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1994.tb00593.x

99. Potter CG, Ramshaw AL, Stickland JE**, Parums DV**, McGee JO'D. Quantification of specific mRNA by flat-bed scintillation counting of dual-labelled dot blots. Biotechniques. 1993 Oct;15(4):738-43. PMID: 8251177.

100. Wood KM, Cadogan MD, Ramshaw AL, **Parums DV**. The distribution of adhesion molecules in human atherosclerosis. Histopathology. 1993 May;22(5):437-44. doi: 10.1111/j.1365-2559.1993.tb00157.x. PMID: 7688340. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1993.tb00157.x

101. Ramshaw AL, **Parums DV**. The distribution of adhesion molecules in chronic periaortitis. Histopathology. 1994 Jan;24(1):23-32. doi: 10.1111/j.1365-2559.1994.tb01267.x. PMID: 7511559. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1994.tb01267.x

102. Paul J, Baigrie C, **Parums DV**. A fatal case of disseminated infection with the turtle bacillus, *Mycobacterium chelonae*. J Clin Pathol. 1992 Jun;45(6):528-30. doi: 10.1136/jcp.45.6.528. PMID: 1624602. Available from: https://jcp.bmj.com/content/jclinpath/45/6/528.full.pdf

103. Davies AH, **Parums DV**. Storage of donor long saphenous vein. J Cardiovasc Surg (Torino). 1992 Jan-Feb;33(1):92-7. PMID: 1545005.

104. Ramshaw AL, **Parums DV**. Combined immunohistochemical and immunofluorescence method to determine the phenotype of proliferating cell populations. J Clin Pathol. 1992 Nov;45(11):1015-7. doi: 10.1136/jcp.45.11.1015. PMID: 1485903. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC495036/

105. **Parums DV**, Choudhury RP, Shields SA, Davies AH. Characterization of inflammatory cells associated with idiopathic retroperitoneal fibrosis. Br J Urol. 1991 Jun;67(6):564-8. doi: 10.1111/j.1464-410x.1991.tb15216.x. PMID: 2070198. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1464-410X.1991.tb15216.x

106. McKee G, **Parums DV**. False positive cytodiagnosis in fibrosing alveolitis. Acta Cytol. 1990 Jan-Feb;34(1):105-7. PMID: 2296835.

107. Cawthorn SJ, **Parums DV**, Gibbs NM, A'Hern RP, Caffarey SM, Broughton CIM, Marks CG. Extent of mesorectal spread and involvement of lateral resection margin as prognostic factors after surgery for rectal carcinoma. Lancet. 1990 May 5;335(8697):1055-9. doi: 10.1016/0140-6736(90)92631-q. PMID: 1691810. Available from: https://www.thelancet.com/journals/lancet/article/PII0140-6736(90)92631-Q/fulltext

108. **Parums DV**, Dunn DC, Dixon AK, Mitchinson MJ. Characterization of inflammatory cells in a patient with chronic periaortitis. Am J Cardiovasc Pathol. 1990;3(2):121-9. PMID: 2264985.

109. **Parums DV**. Inflammatory mediators and atherosclerosis. Biochem Soc Trans. 1990 Dec;18(6):1069-72. doi: 10.1042/bst0181069. PMID: 2088809. Available from: https://portlandpress.com/biochemsoctrans/article/18/6/1069/82423/Inflammatory-mediators-in-atherosclerosis

110. **Parums DV**, Brown DL, Mitchinson MJ. Serum antibodies to oxidized LDL and ceroid in chronic periaortitis. Arch Pathol Lab Med. 1990 Apr;114(4):383-7. PMID: 2322097.

111. **Parums DV**. The spectrum of chronic periaortitis. Histopathology. 1990 May;16(5):423-31. doi: 10.1111/j.1365-2559.1990.tb01541.x. PMID: 2193863. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1990.tb01541.x

112. Ramshaw AL, **Parums DV**. Immunohistochemical characterization of inflammatory cells associated with advanced atherosclerosis. Histopathology. 1990 Dec;17(6):543-52. doi: 10.1111/j.1365-2559.1990.tb00794.x. PMID: 2076887. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2559.1990.tb00794.x

113. **Parums DV**, Cordell JL, Micklem K, Heryet AR, Gatter KC, Mason DY. JC70 (CD31): A new monoclonal antibody that detects vascular endothelium-associated antigen on routinely processed tissue sections. J Clin Pathol. 1990 Sep;43(9):752-7. doi: 10.1136/jcp.43.9.752. PMID: 2212067. Available from: https://jcp.bmj.com/content/jclinpath/43/9/752.full.pdf

114. **Parums DV**. Studies on Inflammation in Atherosclerosis. PhD thesis. University of Cambridge, 1987.

115. **Parums DV**, Chadwick DR, Mitchinson MJ. The localisation of immunoglobulin in chronic periaortitis. Atherosclerosis. 1986 Aug;61(2):117-23. doi: 10.1016/0021-9150(86)90070-5. PMID: 3530262. Available from: https://www.atherosclerosis-journal.com/article/0021-9150(86)90070-5/pdf

116. **Parums DV**, Mitchinson MJ. Demonstration of immunoglobulin in the neighbourhood of advanced atherosclerotic plaques. Atherosclerosis. 1981 Jan-Feb;38(1-2):211-6. doi: 10.1016/0021-9150(81)90118-0. PMID: 7470201.

Contributions to Books and Periodicals:

1. **Parums DV.** Pathological Characterisation of Ischaemic Injury. In: Ischaemia Reperfusion Injury Eds. Grace P, Mathie R. Blackwell Science, 1999. ISBN10 0632050217. Available from: https://www.bookdepository.com/book/9780632050215
2. **Parums DV.** Inflammation and atherosclerosis. In: Pathology of Blood Vessels. Eds. Stehbens WE, Lie JT. Chapman and Hall. 1995. ISBN-10: 0-412-48640-7. pp. 329-353. Available from: https://www.gettextbooks.co.uk/isbn/9780412486401/
3. **Parums DV**. Histochemistry and immunochemistry of vascular diseases. In: Pathology of Blood Vessels. Eds. Stehbens WE, Lie JT. Chapman and Hall. 1995. ISBN-10: 0-412-48640-7. pp. 313-329. Available from: https://www.gettextbooks.co.uk/isbn/9780412486401/
4. **Parums DV.** The Distribution of Adhesion Molecules in Normal and Atherosclerotic Arteries and Aortas. In: Cardiovascular Disease: Cellular and Molecular Mechanisms, Prevention and Treatment. Ed. L. Gallo. Plenum Publishing Corporation, 1994. ISBN 978-1-4613-5805-3; ISBN 978-1-4615-1959-1 (eBook); doi: 10.1007/978-1-4615-1959-1. Available from: https://link.springer.com/chapter/10.1007/978-1-4615-1959-1_21
5. **Parums DV**. Chronic periaortitis. In: Oxford Textbook of Surgery. 1st Ed. Eds. Morris, P.J. & Malt, R.A. Oxford University Press. ISBN-10: 0192618008. ISBN-13: 978-019261800. 1994, pp. 329-331. Available from: https://www.amazon.co.uk/Oxford-Textbook-Surgery-Peter-Morris/dp/0192618008
6. **Parums DV**. The pathobiology of vasculitis. In: Oxford Textbook of Surgery. 1st Ed. Eds. Morris, P.J. & Malt, R.A. Oxford University Press. 1564 pages. ISBN-10: 0192618008. ISBN-13: 978-019261800. 1994, pp. 325-328. Available from: https://www.amazon.co.uk/Oxford-Textbook-Surgery-Peter-Morris/dp/0192618008
7. **Parums DV.** The pathobiology of atherosclerosis. Oxford Textbook of Surgery. Eds. Morris, P.J. & Malt, R.A. Oxford University Press. ISBN-10: 0192618008. ISBN-13: 978-019261800. 1994. pp. 319-324. Available from: https://www.amazon.co.uk/Oxford-Textbook-Surgery-Peter-Morris/dp/0192618008
8. **Parums DV.** Macrophages in cardiovascular disease. Chapter 9. In: The Natural Immune System - Volume II: The Macrophage. Ed. Lewis CE, McGee JO'D. IRL Press, Oxford. ISBN: 9780199632350. 1992, pp.361- 390. Available from: https://www.amazon.co.uk/Macrophage-Natural-Immune-System/dp/0199632359
9. **Parums DV.** Aortic atherosclerosis: pathogenesis and local complications. Oxford Textbook of Pathology. Eds. McGee JO'D, Isaacson PG, Wright NA. Oxford University Press, 1992. ISBN: 019 261 9721 and 019 261 9748. Chapter. 12.3, pp. 812-22. Available from: https://www.amazon.co.uk/Oxford-Textbook-Pathology-Principles-Publications/dp/0192619721
10. **Parums DV.** Armstrong, R. Clinical pathology teaching in Oxford. Oxford Medical School Gazette. 1990; 41:31-34.
11. Mitchinson MJ, Ball RY, Carpenter KLH, **Parums DV**. Macrophages and ceroid in atherosclerosis. In: Hyperlipidaemia and atherosclerosis, Suckling, K.E., Groot, P.H.E. (Eds.), Academic Press, London. ISBN 10: 0126756457. ISBN 13: 9780126756456. 1988 pp. 117-134. Available from: https://www.amazon.com/Hyperlipidaemia-Atherosclerosis-Keith-Suckling/dp/0126756457

Online Articles:

LinkedIn Pulse

1. Medical Journalism: time for involvement by the medical profession. By Dr Dinah Parums https://www.linkedin.com/pulse/medical-journalism-time-involvement-profession-dinah-parums
2. Good Publication Practice Guideline 3 (GPP3). August 2015. By Dr Dinah Parums. https://www.linkedin.com/pulse/good-publication-practice-guideline-3-gpp3-august-2015-dinah-parums?trk=prof-post

***Healthcare-Arena*, published by Pentland Medical. Original Articles -** https://healthcare-arena.co.uk/author/dinahparums/

1. Is There a Role for Humour in Medicine? If so, what is it? For Healthcare-Arena. Illustrated by Fran Orford. https://healthcare-arena.co.uk/is-there-a-role-for-humour-in-medicine/
2. Chronic Hepatitis C Infection. NHS England has now agreed to increase the funding of new treatments. For Healthcare-Arena. Illustrated by Fran Orford. https://healthcare-arena.co.uk/chronic-hepatitis-c-infection/

3. The NHS Goes Back to the Future in 2015. NHS England's CEO outlines the implementation of the 'Five Year Forward View' at this year's NHS Confederation conference. For Healthcare-Arena. https://healthcare-arena.co.uk/the-nhs-goes-back-to-the-future-in-2015/
4. Meningitis B Vaccine. England and Scotland are first to implement a national vaccination programme: but who will follow? For Healthcare-Arena. https://healthcare-arena.co.uk/meningitis-b-vaccine/
5. Social Prescribing. See your GP and leave with a prescription for a pet or a new hobby? For Healthcare-Arena. Illustrated by Fran Orford. https://healthcare-arena.co.uk/social-prescribing/
6. Treatment for Advanced Melanoma Using T-VEC. By Dr Dinah Parums. A Herpes Simplex Virus Type 1-derived oncolytic immunotherapy: – separating fact from fiction.Illustrated by Fran Orford. https://healthcare-arena.co.uk/treatment-for-advanced-melanoma-using-t-vec/
7. Personalised Microbial Health. By Dr Dinah Parums. Microbiome data now being gathered may form the basis for a 'personalised' approach to improving individual microbial populations. https://healthcare-arena.co.uk/personalised-microbial-health/
8. The Carter Review. Procurement in the NHS. By Dr Dinah Parums. Standardisation is predicted to save the NHS £5bn a year by 2020. https://healthcare-arena.co.uk/the-carter-review-procurement-in-the-nhs/
9. Carbapenem-Resistant Enterobacteriaceae (CRE): an Update. By Dr Dinah Parums. Antimicrobial Research Collaborative (ARC) recommends CRE screening as a priority for admissions to high-risk spehttps://healthcare-arena.co.uk/carbapenem-resistant-enterobacteriaceae-cre/

Marketing Product Insights – for Pentland Medical

1. ABLiS™ – Antimicrobial Basin and Liner System. Pentland Medical Product Insight written by Dr Dinah Parums. An innovative bed-bathing system providing cost-effective comfort and prevention of healthcare-associated infection (HAI). https://healthcare-arena.co.uk/ablis-antimicrobial-basin-and-liner-system/
2. Medspira Breath Hold. Pentland Medical Product Insight written by Dr Dinah Parums. Safe, reliable, accurate and affordable respiratory control technology to protect patients during imaging and radiotherapy. https://healthcare-arena.co.uk/medspira-breath-hold/
3. The Nasal Alar SpO2 Sensor. Pentland Medical Product Insight written by Dr Dinah Parums. Accurate long-term pulse oximetry monitoring with greater patient comfort, lower cost and application beyond the ICU. https://healthcare-arena.co.uk/the-nasal-alar-spo2-sensor/

Meeting Abstracts (1985 to 2008):

2007:

- Donovan, M.J., Kotsianti, A., Bayer-Zubek, V., Verbel, D., Clayton, M., Hamann, S., Capodieci, P., Pang, H., Cordon-Cardo, C., **Parums, D**., Holloway, B. *A systems pathology model for predicting overall survival in patients with refractory, advanced non small cell lung cancer (NSCLC) treated with gefitinib.*ASCO Annual Meeting Proceedings 2007, 25(18): 18065.

2005:

- Wookey, A, Ellison, G, Donald, E, McCormick, R, Smith, J, **Parums, D**, Flannery, A, Gibson, N, March, R.*Genetic Heterogeneity of Tumours and implications for Epidermal Growth Factor Receptor Mutation Detection in Non Small Cell Lung Cancer Patients.* Abstract and Poster 3390. *AACR*, April 2005.

2001:

- Torsney, E., Charlton, R.G., Arthur, H. **Parums, D.V**. *Endoglin, a gene required for murine embryonic vasculogenesis is upregulated in angiogenesis in human inflammatiory disease: studies using a 'knockout' mouse model (the 'Cookson Mouse')*. J Pathol 2001, 193: 9A-9A.
- Katz, S.D., Parums, D.V.*Sympathetic activity by sildenafil*. Circulation 2001, 104(22):e119-e120.
- Charlton, R.G., **Parums, D.V.***Transforming growth factor-beta1 (TGF-bet1) expression by myofibroblasts in dermal wound healing.* J Pathol 2001, 193: 8A-8A.

2000:

- Charlton, R.G., Thompson, L., Phillips, S., Ridden, J., Cindrova, T., Johnson, N., **Parums, D.V.***LIP-1 (PDE-5A1); A marker for human smooth muscle cells and myofibroblasts*. J Pathol 2000, 192: 27A-27A.
- **Parums, D.V.**, Charlton, R.G., Johnson, N., Cindrova, T., Skepper, J., Phillips, S.*Immunohistochemistry (IHC), in situ hybridization (ISH) and biochemical characterization of phosphodiesterase type 5 (PDE5) in normal and ischaemic cardiac tissue.* European Heart Journal 2000, 21: 616-616.
- Torsney, E., Charlton, R.G., Arthur, H., **Parums, D.V.***An antibody to endoglin/CD105 (SN6h): a marker for endothelial cells in chronic inflammatory disease.*J Pathol 2000, 192: 27A-27A.

- Charlton, R.G., **Parums, D.V.***Characterisation of the cellular components of chronic skin wounds: the role of cytokines (VEGF, bFGF and TGFbeta) in angiogenesis and fibrosis.* J Pathol 2000, 192: 30A-30A. **(July 2000 Poster Prize from the Pathological Society of Great Britain & Ireland)**

1999:

- Charlton, R., Thompson, L., Turley, H., Gatter, K., **Parums, D.V.***A new monoclonal antibody to VEGF (VG1) can be used to study angiogenesis in fixed material*. J Pathol 1999, 187: 36A-36A.
- **Parums, D.V.,** Ashton, M., Charlton, R., Holter, J., Ridden, J.*Novel endothelial cell markers are expressed in angiogenesis in human atherosclerosis.* J Pathol 1999, 187: 12A-12A.
- Charlton, R., Holter, J., Ridden, J., Thompson, L., **Parums, D.V.***The expression of C5a receptor (C5aR)(CD88) is associated with the progression of inflammation in human disease.* J Pathol 1999, 187: 36A-36A.

1998:

- **Parums, D.V.**, Walton, L.J., Powell, J.T. *Unrestricted usage of immunoglobulin heavy chain genes in adventitial B-lymphocytes in atherosclerotic aortic aneurysms.*J Pathol 1998, 184: 32A-32A.
- Jalini, L., Angus, B., **Parums, D.V.***Post-transplant lymphoproliferative disease (PTLD) in heart and lung transplant patients at the Freeman Hospital.* J Pathol 1998, 184: 35A-35A.
- Charlton, R.G., Neal, D.E., Morley, A.R., **Parums, D.V.***A morphometric study of nerve, muscle and connective tissue in the 'unstable' bladder*. J Pathol 1998, 184: 40A-40A.

1997:

- **Parums, D.V.**, Martin, A., Belgore, F., Chung, N.*Angiogenesis is associated with the progression of human atherosclerosis to clinically significant disease*. J Pathol 1997, 182: A13-A13.
- Kumar, R., Smith, D.A., **Parums, D.V.***Cytopathology, immunohistochemistry and electronmicroscopy in the diagnosis of a case of epithelioid haemangio-endothelioma (EHE) of the lung.* J Pathol 1997, 182: A28-A28.
- **Parums, D.V.**, Chung, N., Ludbrook, V., Houston, P., Campbell, C.J., Wells, T.N.C.*Specific chemokine receptors are associated with angiogenesis and leukocyte recruitment in human atherosclerosis.* J Pathol 1997, 82: A13-A13.
- **Parums, D.V.**, Pignatelli, M.*The localization of novel endothelial cell (EC) markers in angiogenesis in human atherosclerosis.* J Pathol 1997, 182: A41-A41.
- Johnson, N., Ashcroft, T., **Parums, D.V**. *The role of calretinin in the diagnosis of mesothelioma.*J Pathol 1997, 182: A28-A28.

1996:

- Walton, L.J., **Parums, D.V.**, Powell, J.T.*B cells infiltrating abdominal aortic aneurysms are polyclonal*. Immunology 1996, 89: BB304-BB304.
- **Parums, D.V.**, Pignatelli, M.*Localisation of novel endothelial cell markers in human advanced atherosclerosis.* Tissue Antigens 1996, 48(4-II): EC105-EC105.
- Ashton, M.D., **Parums, D.V.**, Standfield, N.*Characterisation of arterio-venous malformation (AVM).* J Pathol 1996, 179: A47-A47.
- **Parums, D.V.**, Chung, N., Belgore, F.*Tumour necrosis factor alpha (TNF-alpha) is involved in the progression of human atherosclerosis*. J Pathol 1996, 179: A46-A46.
- **Parums, D.V.**, Chung, N., Ludbrook, V., Houston, P., Black, D., Wells, T.*The localization of novel chemokine receptors in human atherosclerosis*. J Pathol 1996, 179: A46-A46.
- **Parums, D.V.**, Ashton, M.D., Mason, J.C., Haskard, D.O.*Thy-1 expression by new vessels associated with atherosclerosis.* J Pathol 1996, 179: A46-A46.

1994:

- **Parums, D.V.**, Ramshaw, A.L.*Expression of adhesion molecules and cytokine genes in aortic adventitial chronic inflammation associated with advanced atherosclerosis (chronic periaortitis).* Journal of Cellular Biochemistry 1994, 56: 298-298.

1991:

- Ramshaw, A.L., Stickland, J.E., Baigrie, R.J., **Parums, D.V.***Cytokine and cytokine receptor expression associated with advanced atherosclerosis.* J Pathol 1991, 164(4): A348-A348.
- Ramshaw, A.L., **Parums, D.V.***Inflammatory cells in chronic periaortitis are activated and proliferating.* J Pathol 1991, 163(2): A162-A162.

1990:

- Ramshaw, A.L., **Parums, D.V.** *Immunohistochemical characterization of inflammatory cells in biopsies from atherosclerotic abdominal aortic aneurysms*. J Pathol 1990, 160(2): A160-A160.
- **Parums, D.V.***Inflammatory mediators in atherosclerosis*. Biochem Soc Trans 1990, 18: 1069-1072. http://www.biochemsoctrans.org/bst/018/bst0181069.htm

1987:

- **Parums, D.V.**, Mitchinson, M.J.*Serum antibodies to oxidized LDL and ceroid in chronic periaortitis*. J Pathol 1987, 151(1): A57-A57.

1985:

- **Parums, D.V.**, Mitchinson, M.J.*Auto-Allergy in Atherosclerosis.* J Pathol 1985, 146(3): A245-A245.

Patents by Inventor Dr Dinah Parums (US and Europe)

US Patents:

This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

Available from: https://patents.justia.com/inventor/dinah-parums

&

https://www.paperdigest.org/expert/?name=dinah_parums

1. **Treatment of Wounds**

Publication number: 20050148585

Abstract: This invention relates to the use of cyclic guanosine 3', 5'-monophosphate type five (cGMP PDE5) inhibitors (from now on PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin, including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.

Type: Application

Filed: August 26, 2004

Publication date: July 7, 2005

Inventors: Michael Davies, Jonathan Huggins, **Dinah Parums**

Available from: https://patents.justia.com/inventor/dinah-parums

2. 12 Amino Acid Sequence

Publication number: 20050106638

Abstract: The invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.

Type: Application

Filed: August 30, 2004

Publication date: May 19, 2005

Applicant: Pfizer Inc.

Inventors: Dinah Parums, Stephen Phillips, John Ridden

Available from: https://patents.justia.com/inventor/dinah-parums

& https://europepmc.org/article/PAT/US2005106638

3. **Target**

Patent number: 6794192

Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.

Type: Grant

Filed: June 28, 2001

Date of Patent: September 21, 2004

Assignee: Pfizer Inc.

Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden

Available from: https://patents.justia.com/inventor/dinah-parums

4. **Target**

Publication number: 20030040041

Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.

Type: Application

Filed: June 28, 2001

Publication date: February 27, 2003

Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden

Available from: https://patents.justia.com/inventor/dinah-parums

5. **Treatment of Wounds**

Publication number: 20020065286

Abstract: This invention relates to the use of cyclic guanosine 3′, 5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of chronic wounds of a non-diabetic origin including in particular chronic venous ulcers, chronic decubitus (pressure sores) and arterial ulcers; and acute wounds.

Type: Application

Filed: August 10, 2001

Publication date: May 30, 2002

Inventors: Michael John Davies, Jonathan Paul Huggins, **Dinah Parums**

Available from: https://patents.justia.com/inventor/dinah-parums

& https://patentimages.storage.googleapis.com/bd/94/9d/b50fc52e4c9425/US20020065286A1.pdf

European Patents:

6. Phosphodiesterase

Priority number: GB20000016009

Application number: EP20010305392

Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.

Type: Application

Filed: 21 Jun 2001

Publication date: 21 Jun 2001

Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden

Available from: http://europepmc.org/article/PAT/EP1178115#